PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors

The following is a detailed description of the objectives of the study: Main objectives: * Application of novel radionuclide-labeled HER2-targeting molecular probes (89Zr-LNCab103 and 89Zr-LNCab104) in the early diagnosis of breast cancer, gastric cancer, urothelial carcinoma and other diseases; * To evaluate the efficacy, safety and dosimetry of 89Zr-LNCab103 and 89Zr-LNCab104 in clinical PET imaging applications. Secondary Objectives: * To investigate the biodistribution of 89Zr-LNCab103 and 89Zr-LNCab104 in patients with breast cancer, gastric cancer and urothelial carcinoma, including the distribution of primary and metastatic tumors and normal tissues, through the evaluation of whole-body imaging and SUV values using PET/CT imaging. * Compared with 18F-FDG, the clinical application value and diagnostic advantages of the novel radionuclide-labeled HER2-targeting molecular probes 89Zr-LNCab103 and 89Zr-LNCab104 were evaluated.